The HNRNPUL2 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to eliminate HNRNPUL2 expression in the HeLa background. This product provides a validated loss-of-function model for investigating the multifunctional roles of HNRNPUL2 in DNA damage repair and pre-mRNA processing. The pooled polyclonal population ensures robust representation of disruptive edits while minimizing clonal artifacts, making it suitable for functional genomics studies requiring consistent gene disruption across populations.
The host HeLa cell line is derived from a human cervical adenocarcinoma and is notable for its integration of human papillomavirus type 18 (HPV18). The viral oncoproteins E6 and E7 mediate degradation of the tumor suppressor p53 and inactivation of the retinoblastoma protein (Rb), respectively, creating a genetic environment that mimics key aspects of cervical carcinogenesis. This well-characterized epithelial model is widely employed in cancer biology, drug response, and DNA repair studies, providing a hyperproliferative but genomically unstable background ideal for assessing tumor-specific repair dependencies.
HNRNPUL2 encodes a heterogeneous nuclear ribonucleoprotein that scaffolds the BRCA1-A complex, a central regulator of homologous recombination repair. Downstream of ATM/ATR-mediated damage signaling, HNRNPUL2 promotes DNA end resection by directly interacting with BRCA1 and CtIP (RBBP8). This facilitates loading of RAD51 recombinase onto RPA-coated ssDNA, a critical strand invasion step. HNRNPUL2 also engages the MRE11-RAD50-NBS1 (MRN) sensor complex, bridging initial break detection to resection. Additionally, HNRNPUL2 functions in alternative splicing and mRNA transport, linking DNA repair with post-transcriptional gene regulation.
In the HeLa context, loss of HNRNPUL2 is particularly informative given the cell line??s compromised p53 and Rb checkpoints, which elevate reliance on backup repair pathways. Abrogation of HNRNPUL2-dependent resection may sensitize these cells to DNA-damaging agents or PARP inhibitors, offering a platform to dissect synthetic lethal interactions relevant to breast and ovarian cancers that harbor BRCA pathway defects. Furthermore, the dual RNA-processing functions of HNRNPUL2 can be probed in this background to explore how HPV-driven transcriptional rewiring intersects with the DNA damage response, potentially uncovering novel vulnerabilities in cervical cancer.
Researchers can employ the HNRNPUL2 polyclonal knockout HeLa cells in a broad range of assays, including Western blotting for ??H2AX, immunofluorescence for RAD51 foci, and DR-GFP reporter assays. RNA-seq and RT-qPCR enable transcriptome-wide and targeted expression profiling to dissect HNRNPUL2??s splicing regulatory network. Co-immunoprecipitation with BRCA1 validates complex integrity. These applications make the cells a powerful tool for studying DNA repair, cancer drug resistance, and RNA biology. For additional technical details or to inquire about custom panels, contact Ascent Research.
